M&As this week: Shanghai Pharmaceutical, Sapphire I (HK) Holdings, Sumitomo Corporation of America

Shanghai Pharmaceutical plans to acquire Cardinal Health China business from US-based healthcare company Cardinal Health for $1.2bn.

The divestiture will enable the Chinese pharmaceutical company to strengthen its distribution network.

Sapphire I (HK) Holdings has acquired a 49% stake in Chinese pharmaceutical company Hisun-Pfizer Pharmaceuticals from Pfizer.

The divestment enables both Hisun and Pfizer to concentrate on their core businesses.

Sumitomo Corporation of America (SCA) plans to acquire a 20% stake in US-based generic drug manufacturer Sawai America Inc (SAI) from Sawai Pharmaceutical (SPCL) for $211m.

SCA, a subsidiary of Sumitomo Corporation, is a transport and logistics services provider, while SPCL is a generic pharmaceuticals manufacturer.

Both companies involved in the acquisition are based in Japan.

Grupo Biotoscana SL has acquired pharmaceutical manufacturer Laboratorio DOSA S.A. for BRL100m ($30.48m).

The acquisition will enable the specialist therapeutic products developer to expand its product portfolio and geographic reach.